Bahar Laderian
Hematology & Oncology · Cleveland, OHNPI 1992123970
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $26,647 with a category attached, or 93.8%. Merck accounts for 93.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $25,000 and has fallen 97.9% since, to $524 in 2025.
Across 19 payments — averaging $1402.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$25K
- Pfizer$622
- Novartis$231
- Exelixis Inc.$175
- Seagen Inc.$152
- Array Biopharma Inc$139
- plus $329 from 4 others
Across 9 payments — averaging $1399.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$13K
What the payments were for
- Grants$25,00094%
- Food & beverage$1,6476%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $25,000 |
| Pfizer | 4 | $622 |
| Novartis | 6 | $231 |
| Exelixis Inc. | 1 | $175 |
| Seagen Inc. | 1 | $152 |
| Array Biopharma Inc | 1 | $139 |
| AstraZeneca | 1 | $135 |
| Caris MPI, Inc. | 1 | $83 |
| Boehringer Ingelheim | 1 | $56 |
| Tempus AI, Inc | 2 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,647 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 11 | $21,714 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.